



Current as of August 28, 2024

Poster Session A (To be presented Sunday, September 15, 7:45-10p.m.)

A001 An open label, phase II trial of ERK inhibition alone and in combination with autophagy inhibition in patients with metastatic pancreatic cancer. Rishi Surana. Dana-Farber Cancer Institute, Boston, MA, United States.

A002 Phase II Trial of Vemurafenib + Sorafenib in Advanced KRAS Mutated Pancreas Cancer. Erkut Borazanci. HonorHealth Research Institute, Scottsdale, AZ, United States.

A003 Phase 2 Trial Testing The PARP Inhibitor Niraparib In Patients With Advanced Pancreatic Cancer with Pathogenic Variants In BRCA 1, BRCA2, PALB2, ATM and CHEK2. Brandon Huffman. Dana-Farber Cancer Institute, Boston, MA, United States.

A004 A Phase 1B/2 trial of second line immunotherapy with pepinemab and avelumab for patients with metastatic pancreatic adenocarcinoma. Luis Ruffolo. University of Rochester Medical Center, Rochester, NY, United States.

A005 Systemic targeting of therapeutic RNA to pancreatic ductal adenocarcinoma via a novel, cell-penetrating, and nucleic acid-binding monoclonal antibody. Diana Martinez-Saucedo. Yale School of Medicine, New Haven, CT, United States.


A006 Generation of a flexible pancreatic cancer mouse model via somatic tissue engineering. Ziyue (Zoey) Yang. Baylor College of Medicine, Houston, TX, United States.

A007 Uncovering molecular differences in pancreatic ductal adenocarcinoma tissues from Black and White patients in the US. Saurabh Mandal. Henry Ford Health, Detroit, MI, United States.

A008 The effect of body mass index on Tumor Treating Fields (TTFields) intensity distribution in the abdomen: results of a simulation model study. Ariel Naveh. Novocure Ltd, Haifa, Israel.

A009 Mutant KRAS in Circulating Tumor DNA Assessed by Digit Droplet PCR as a Biomarker in Pancreatic Cancer in Patients Treated with Neoadjuvant Chemotherapy. Dominic Vitello. Northwestern University Feinberg School of Medicine Department of Surgery, Chicago, IL, United States.

A010 A patient first approach using CRISPR-directed gene editing as an augmentative therapy for the treatment of pancreatic ductile adenocarcinoma. Eric Kmiec. Gene Editing Institute, Newark, DE, United States.



A011 Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1. Lokesh Akana. University of Arkansas for Medical Sciences (UAMS), Little rock, AR, United States.

A012 Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in Pancreatic Adenocarcinoma patients harboring unresectable tumors treated with modified FOLFIRINOX or FOLFIRINOX regimen. Wen-Han Chang. Oncotelic Therapeutics Inc, Agoura Hills, CA, United States.

A013 Advanced Gene Signatures for the Diagnosis and Personalized Treatment of Pancreatic Ductal Adenocarcinoma. Ashish Manne. The Ohio State University, Columbus, OH, United States.

A014 Protein-informed gene methylation signatures to predict treatment response and outcomes in pancreatic ductal adenocarcinoma. Ashish Manne. The Ohio State University, Columbus, OH, United States.

A015 Tissue MUC5AC expression predicts recurrence patterns following resection in pancreatic ductal adenocarcinoma. Ashish Manne. The Ohio State University, Columbus, OH, United States.

A016 Functional characterization of the 1p36.33 pancreatic cancer GWAS locus. Katelyn Connelly. National Cancer Institute, Rockville, MD, United States.

A017 Comprehensive evaluation of the therapeutic effects of whole-body hyperthermia for pancreatic ductal adenocarcinoma (PDAC) and the potential synergy with standard-of-care chemotherapeutics. Robin Colenbier. University of Antwerp, Antwerp, Belgium.

A018 The functional characterization of pancreatic ductal adenocarcinoma GWAS risk variants in primary pancreatic cells – A pilot study. Minal Patel. NCI, Rockville, MD, United States.

A019 Black race and CA 19-9 nonproduction is associated with limited pathologic response to neoadjuvant chemotherapy in patients with localized pancreatic cancer. Mary Martos. University of Miami Miller School of Medicine, Miami, FL, United States.

A020 Exocytosed amino acids as a selective and side effect-free therapy for pancreatic cancer. Alfred Akinlalu. University of Denver, Denver, CO, United States.

A021 In silico Prediction of Proteins Interacting with a Basal-like Pancreatic Cancer marker, RhoV, Using AlphaFold. Zebang Li. Alpert Medical School of Brown University, Providence, RI, United States.



A022 Neoadjuvant ablative radiation downstages high-risk features and alters immune response in pancreatic cancer. Todd Aguilera. University of Texas Southwestern Medical Center, Dallas, TX, United States.

A023 Patient-Derived Organoid Cultures for Personalized Therapies and Targeted Drug Screening Applications. Constanza Tapia Contreras. University Medical Center Göttingen, Göttingen, Germany.

A024 ABO blood type and overall survival in patients with pancreatic adenocarcinoma: A systematic review and meta-analysis. Tulio L Correa. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

A025 Cell of origin does not underlie transcription heterogeneity in pancreatic ductal adenocarcinoma. Janel Kopp. University of British Columbia, Vancouver, BC, Canada.

A026 Studying the synergistic potential of a p53 reactivator with ROS-mediated therapies for the treatment of pancreatic cancer. Daniel Parra Sánchez. University College London, London, United Kingdom.

A027 Enhancing pancreatic cancer chemotherapy through photochemical internalisation. Maria Rosado. University College London, London, United Kingdom.

A028 MTAP deficiency is frequent and mostly homogeneous in ductal adenocarcinomas of the pancreas. Katharina Teljuk. University Medical Center Hamburg-Eppendorf, Hamburg, Germany.


A029 Evaluating and interpreting scGPT: A foundation model for single-cell biology in real-world cancer clinical trial data. Runzi Tan. Dana-Farber Cancer Institute, Boston, MA, United States.

A030 Modulation of lymphocyte adhesion and migration by iCAF and myCAF fibroblasts in PDAC. Fouzia Zayou. University of Birmingham, Birmingham, United Kingdom.

A031 Identification of therapeutic vulnerabilities in the subset of pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency. Mathias Tesson. CRUK Scotland Institute, Glasgow, United Kingdom.

A032 Cancer associated fibroblasts drive classical to basal change associated with increased T cell presence in pancreatic ductal adenocarcinoma. Jacquelyn Zimmerman. Johns Hopkins University School of Medicine, Baltimore, MD, United States.

A033 Mapping age-specific biomarker dynamics in pancreatic ductal adenocarcinoma. Priyanka Gupta. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.



A034 KRAS Mutation-Specific effects on the Tumor Immune Microenvironment Drive Tumor Progression. Despina Siolas. Weill Cornell Medicine, New York, NY, United States.

A035 3D High-Density Collagen I Improves the Modeling of Aggressive Pancreatic Cancer. Kim Nguyen-Ta. University of California, San Diego, San Diego, CA, United States.

A036 The role of hypoxia in CD8+ T cell localization and function in pancreatic cancer. Ashley Mello. University of Michigan, Ann Arbor, MI, United States.

A037 Role of hypoxia in fibroblast reprogramming in pancreatic cancer. Tenzin Ngodup. University of Michigan, Ann Arbor, MI, United States.

A038 The hypoxic regulation of macrophage function in pancreatic cancer. Sean Hannifin. University of Michigan, Ann Arbor, MI, United States.

A039 Repeat RNA mediated disruption of cellular plasticity in pancreatic cancer. Eunae You. Mass General Cancer Center, Charlestown, MA, United States.

A040 Multiplex fluorescent immunohistochemistry reveals immunosuppressive tumor microenvironment in COMPASS-like complex gene mutated pancreatic cancer. Shungang Zhang. University of Michigan, Ann Arbor, MI, United States.

A041 Deciphering the bidirectional influences of sympathetic neurons and cancer associated fibroblasts and the resulting contributions to PDAC progression. Ariana Sattler. Oregon Health and Science University, Portland, OR, United States.


A042 Clinical classification of cancer-associated fibroblast subtypes predicts prognosis and treatment response. Xianlu Peng. The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

A044 Persistence of fetal splanchnic gene signature defines a tumor-restraining fibroblast subtype in pancreatic cancer. Lu Han. Medical University of South Carolina, Charleston, United States.

A045 Disrupting local immunosuppression through combination myCAF/myeloid targeting in pancreatic cancer. Marie Hasselluhn. Columbia University Irving Medical Center, New York, NY, United States.

A046 Spatial transcriptomics reveals heterogeneity of epithelial and stromal compartments in healthy and tumor pancreas. Ahmed Elhossiny. University of Michigan, Ann Arbor, MI, United States.

A047 Fibroblast-specific IL1 receptor inhibition reprograms the inflammatory stroma to overcome the immunosuppressive tumor microenvironment in pancreatic cancer. Camille Acevedo. University of Miami Miller School of Medicine, Miami, FL, United States.



A048 Paricalcitol improves survival in tumor-permissive cancer-associated fibroblast subtype of pancreatic cancers. Jaewon Lee. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

A049 Collagen-driven kinome reprogramming reveals unique, actionable DDR1-signaling dependencies in pancreatic cancer cells. Jean-Philippe Coppe. University of California, San Francisco, San Francisco, CA, United States.

A050 MDSC-derived transmembrane TNF is a central regulator of stromal inflammation and T-cell dysfunction in pancreatic cancer. Andrew Adams. University of Miami, MIAMI, FL, United States.

A051 Innate immune cell dynamics and pancreatic tumor progression in alcoholic pancreatitis. Siddharth Mehra. University of Miami, Miami, FL, United States.

A052 Silencing MICAL2 Expression in Pancreatic Cancer Cells rewires the tumor microenvironment through the IL1-a/p38 MAP kinase/STAT-3 axis and Sensitizes Tumors to Immune Checkpoint Blockade therapy. Bharti Garg. Moores cancer Centre University of California San Diego, San Diego, CA, United States.

A053 Interrogating the spatial biology of pancreatic cancer-associated fibroblasts in resected human pancreatic cancer. Adam Bryce. University of Glasgow, Glasgow, United Kingdom.

A054 Collagen fiber architecture modulates PDAC cell and organoid phenotype. Ciara Doyle. University College Dublin, Dublin, Ireland.


A055 Multiomics profiling reveals druggable tumor-stroma interactions in ATM-deficient pancreatic cancer. Elodie Roger. University Hospital Ulm, Institute of Molecular Oncology and Stem Cell Biology, Ulm, Germany, Ulm, Germany.

A056 Pancreatic ductal adenocarcinoma derived cancer-associated fibroblasts suppress tumor infiltrating lymphocytes in the tumor microenvironment. Charles Bailey. University of Kentucky, Lexington, KY, United States.

A057 Investigating Fibroblast-Epithelial crosstalk in pre-malignant and cancerous microenvironment. Padma Kadiyala. University of Michigan, Ann Arbor, MI, United States.

A058 Primary cancer-associated fibroblasts alter tumor organoid chemosensitivity through epigenetic regulation. Emilie Jaune-Pons. University of Western Ontario, London, ON, Canada.

A059 Understanding the events that promote pancreatic cancer metastasis. Erika Pereira Zambalde. Albert Einstein College of Medicine, New York, NY, United States.



A060 Dysregulation of PTEN expression in a subset of Cancer Associated Fibroblasts by Tumor Secreted Factors in PDAC. Ivo Woogeng. Medical University of South Carolina (MUSC), Charleston, SC, United States.

A061 DKK3 in pancreatic cancer – Elucidating the roles of a double-edged sword. Johann Gout. Institute of Molecular Oncology and Stem cell Biology, University Hospital Ulm, Ulm, Germany.

A062 Neurotropic fibroblast population increases following exposure to chemotherapy in pancreatic adenocarcinoma. Aylin Henstridge. University of Michigan Medicine, Ann Arbor, MI, United States.

A063 The role of JAK/STAT3 signaling in lung premetastatic niche formation and progression. Emily Lasse Opsahl. University of Michigan, Ann Arbor, MI, United States.

A064 Canonical Notch signaling in cancer-associated fibroblasts supports an immunosuppressive pancreatic tumor microenvironment. Allison Bischoff. University of Michigan, Ann Arbor, MI, United States.

A065 Spatial and single cell transcriptomics uncovers metabolic reprogramming and NETosis of neutrophils in human pancreatic cancer. Carson Poltorack. University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States.

A066 nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer. Audrey Hendley. UCSF, San Francisco, CA, United States.


A067 Identifying and targeting FOLFIRINOX resistance mechanisms to improve outcomes in pancreatic cancer. Katie Gordon. Garvan Institute of Medical Research, Sydney, NSW, Australia.

A068 Lfng-expressing centroacinar cell is a prime cell-of-origin for p53-deficient pancreatic cancer. Keli Xu. University of Mississippi Medical Center, Jackson, MS, United States.

A069 Development of an AAV-mediated GEM model to investigate the impact of age on pancreatic tumorigenesis. Karen Duong-Polk. Sanford Burnham Prebys, La Jolla, CA, United States.

A070 Time-Dependent Oxidation and Aggregation of Vimentin upon Binding by β -lap Induced Immunogenic Cell Death. Feng Qian. Tsinghua University, Beijing, China (Mainland).

A071 Inverse Biomarker Exploring Technology (IBMET) Mathematical Identification of Cancer-Specific Epitopes and Novel Targets (Biomarkers) from Big Data of Single-



Domain Antibodies Recognizing Higher Structures. Akihiro Imura. COGNANO, Inc., Kyoto, Japan.

A072 Decoding human kinome specificities through a computational data-driven approach and unveiling kinase activity in pancreatic ductal adenocarcinoma. Li Cai. MD Anderson Cancer Center, Houston, TX, United States.

A073 Desmoglein-2 is a regulator of pancreatic ductal adenocarcinoma progression. Charlie Ffrench. Centre for Cancer biology, Adelaide, South Australia, Australia.

A074 Integrated clinical and single-cell profiling analysis reveals cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. Morteza Chalabi Hajkarim. Columbia University, the Irving Cancer Research Center, New York, NY, United States.

A075 Establishing the interaction mechanism of oncoprotein, Mucin1, and extracellular vesicle marker protein, Alix, in pancreatic cancer. Kristine Hoagstrom. University of Nebraska Medical Center, Omaha, NE, United States.

A076 LINE-1 ORF1p mimics viral innate immune evasion mechanisms in pancreatic cancer. Eunae You. Mass General Cancer Center, Charlestown, United States.

A077 The role of RhoV in basal-like pancreatic cancer. Shang Wu. Tulane University School of Medicine, New Orleans, LA, United States.

A078 Functional screen for mediators of onco-mRNA translation specificity in pancreatic cancer. Joanna Kovalski. UCSF, San Francisco, CA, United States.

A079 SB-216 inhibits oncogenic beta-tubulin subtypes in PDAC. Lauren Gattie. University of Tennessee Health Science Center, Memphis, TN, United States.

A080 An analysis of outcomes in patients (pts) with advanced pancreatic cancer (PDAC) whose tumors harbor pathogenic BRCA1 or BRCA2 mutations based on gene mutation location. Jamie Hur. National Institutes of Health, Bethesda, MD, United States.

A081 Single-cell transcriptomic analysis of organoids derived from normal pancreata reveals epithelial cell heterogeneity and expression of PanIN-associated genes. Alexander Bray. University of Michigan, Ann Arbor, MI, United States.

A082 Defining the lysosome proteome during pancreatic cancer tumor evolution and metastasis. Thuy Nguyen. Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.



A083 Genomic Analysis of Structural Variations in Pancreatic Cancer Using Long-Read Sequencing. Yongxing Du. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Mainland).

A084 CDK12 inhibition drives mitotic catastrophe, triggering genome instability and innate immune response in pancreatic cancer. Dosuke Iwadate. Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.

A085 Engineered novel bioactive Nectin-4 dimer protein significantly enhances the binding of TIGIT. SHIXIA WANG. Conigen Bioscience, Inc., WORCESTER, MA, United States.



Poster Session B (To be presented Monday, September 16, 4:45-7p.m.)

B001 Macrophage adipocyte crosstalk as a node of intervention for pancreatic cancer-associated weight loss. Felix Hambitzer. Dana-Farber Cancer Institute, Boston, MA, United States.

B002 Tumor-secreted PTHrP facilitates pancreatic cancer cachexia by regulation of de novo lipogenesis pathway. Nikita Bhalerao. University of Massachusetts Medical School, Worcester, MA, United States.

B003 Impact of obesity on Pancreaticoduodenectomy procedure perioperative outcomes. Hannah Engebretson. Baylor College of Medicine, Houston, TX, United States.

B004 Targeting Metabolic Vulnerabilities in Pancreatic Cancer: The Synergistic Anti-Tumor Effects of a Ketogenic Diet and IDH1 Inhibition. Omid Hajihassani. Case Western Reserve University, Cleveland, OH, United States.

B005 Characterizing the role of fibroadipogenic progenitors in pancreatic cancer cachexia: the role of miR-27a-3p. Ashok Narasimhan. University of British Columbia, Vancouver, BC, Canada.

B006 The role of tumor specific IGFBP-3 in the onset and progression of skeletal muscle wasting in a murine model of pancreatic cancer. Zachary Sechrist. University of Rochester Medical Center, Rochester, NY, United States.

B007 Optimization of an Orthotopic Mouse Model of Pancreatic Cancer to Simulate Liver Metastasis and Cancer Cachexia. David Wang. Medical University of South Carolina, CHARLESTON, SC, United States.


B008 Twist1 drives pancreatic ductal adenocarcinoma-mediated muscle cachexia. Parash Parajuli. Virginia Commonwealth University, Richmond, VA, United States.

B009 Dietary fats dictate pancreatic cancer fate via phospholipid saturation. Christian Ruiz. Yale University, New Haven, CT, United States.

B010 Endocrine beta-cell stress promotes pancreatic ductal adenocarcinoma through endocrine-exocrine cell crosstalk. Cathy Garcia. Yale University, Hamden, CT, United States.

B011 Predictors of survival and cachexia in pancreatic cancer: results from the CAMPP study. Julie Disharoon. Medical University of South Carolina, Charleston, SC, United States.

B012 Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer: initial results of safety and feasibility of the medically supervised ketogenic diet. Gayle Jameson. HonorHealth Research Institute, Scottsdale, AZ, United States.



B013 Host phenotype profiling predicts progression to resection in neoadjuvant pancreatic cancer. Adam Bryce. University of Glasgow, Glasgow, United Kingdom.

B014 NF- κ B Regulates Innate Immunity in the Muscle Microenvironment to Control Distinct States of Wasting in Pancreatic Cancer-Induced Cachexia. Denis Guttridge. Medical University of South Carolina, Charleston, SC, United States.

B015 Duodenal aspiration biopsy in diagnosis of pancreatic neoplasms. Aleksei Kashintsev. PANDX, London, United Kingdom.

B016 Noninvasive PET imaging and targeted radiotherapy in a chemotherapy induced senescent KPC model with uPAR and IL-6 immunoconjugates. Edwin Pratt. MSKCC, New York, NY, United States.

B017 Disruption of sulfatide metabolism by targeting UGT8 is an actionable metabolic vulnerability for pancreatic cancer early interception. Riccardo Ballarò. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B018 UroPanc: A large prospective observational study for validation of urinary biomarker test for the earlier detection of pancreatic adenocarcinoma. Tatjana Crnogorac-Jurcevic. Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

B019 Sensitivity and specificity of detecting premalignant pancreatic lesions by hyperpolarized magnetic resonance. José Enriquez. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B020 DNA methylation and pancreatic cancer in select gene promoter regions: A repeated measures case-control study of US military service members. Jordan McAdam. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States.

B021 Development of an ultrasensitive sequencing platform for blood-based mutation profiling of pancreas cancer patients. Ryne Ramaker. Duke University, Durham, NC, United States.

B022 Acinar-to-ductal metaplasia index (ADMI): A quantifiable measure of ADM. Pal Koak. Brigham and Women's Hospital/Harvard Medical School, Boston, MA, United States.

B023 Unravelling fibroinflammatory and immune signatures for pancreatic cancer early detection. Pilar Acedo. University College London, London, United Kingdom.



B024 Multiplexed 3D atlas of state transitions and potential prognostic role of poly-ADP ribose glycohydrolase (PARG) in chronic pancreatitis and PDAC. Vidhi Shah. OHSU, Portland, OR, United States.

B025 Surveillance outcome in individuals at high risk of pancreatic cancer. Merav Ben Yehoyada. Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

B026 Development of a Urinary miRNA-Based Classifier for Detecting Pancreatic Cancer in High-Risk Groups. TOMOYA KAWASE. Kawasaki Medical School, Kurashiki, Japan.

B027 A blood-based, multiplex protein biomarker signature shows superior performance in detection of early-stage pancreatic ductal adenocarcinoma (PDAC). Norma Palma. Immunovia Inc, Marlborough, MA, United States.

B028 Meta-analysis of spatial transcriptomics data from pancreatic cancer precursors proposes a common molecular framework for PanIN and IPMN. Matthew Iyer. University of Michigan, Ann arbor, MI, United States.

B029 Repurposing Digital PCR to Diagnose and Create a Novel Genomic Signature for Homologous Recombination Deficiency in Pancreatic Adenocarcinoma. Jennifer Valerin. University of California, Irvine, Orange, CA, United States.

B030 Reprogramming and selective recruitment of distinct neutrophil subpopulations restrain cancer metastasis. Jae Lee. Johns Hopkins University School of Medicine, Baltimore, MD, United States.

B031 Alternate pain management strategies: targeting pancreatic cancer-related pain with Flavonoid. Suheera Haq. University of Connecticut, Storrs, CT, United States.

B032 Evaluating T cell-inflammation in pancreatic neuroendocrine tumors. Joan Miguel Romero. McGill University, Montreal, QC, Canada.

B033 MUC16 - Potential Target for Antibody-based Immunotherapy in Pancreatic Cancer. Prakash Radhakrishnan. Eppley Institute for Research in Cancer and Allied Diseases, omaha, NE, United States.

B034 Myeloperoxidase limits tumor-associated neutrophils mediated immunosuppression in pancreatic cancer. Angisha Basnet. West Virginia University, Morgantown, WV, United States.

B035 Nanoparticle delivery of innate immune agonists combines with senescence-inducing agents to mediate T cell control of pancreatic cancer. Kelly DeMarco. UMass Chan Medical School, Worcester, MA, United States.



B036 Hypoxic cancer cells condition immunosuppressive macrophages via secreted non-protein mediators in pancreatic ductal adenocarcinoma. Matthew Cribb. MD Anderson Cancer Center, Houston, TX, United States.

B037 Banana Lectin expressing CAR T cells to target Pancreatic Cancer. Katie McKenna. Baylor College of Medicine, Houston, TX, United States.

B038 Tumor Derived Parathyroid Hormone Related Protein is an Orchestrator of Immunosuppression in Pancreatic Cancer. Calvin Johnson. University of Massachusetts Chan Medical School, Worcester, MA, United States.

B040 B cells facilitate lymph node colonization in pancreatic ductal adenocarcinoma. Alice Bertocchi. Dana Farber Cancer Institute, Boston, MA, United States.

B041 Fibroblast STAT3 Signaling in Pancreatic Cancer: Implications for Immunotherapy and Tumor Microenvironment Modulation. Samaneh Saberi. Medical University of South Carolina, Charleston, SC, United States.

B042 Dissection of the T cell infiltrate in mouse pancreatic tumors reveals a diverse tumor-reactive T cell repertoire targeting neoantigens and tumor-associated antigens. Stefan Zens. German Cancer research Center, Heidelberg, Germany.

B043 Synergy of Subsumstat and anti-CD40 improves survival by augmenting tumor macrophage infiltration. Asimina Courelli. University of California, San Diego, La Jolla, CA, United States.


B044 Durable T-cell-mediated anti-tumor immune response to pancreatic cancer cells overexpressing interleukin 6. Paige Arneson-Wissink. Oregon Health and Science University, Portland, OR, United States Territories and Minor Outlying Islands.

B045 Sensitizing the PDAC tumor microenvironment to immune checkpoint therapies: characterization of a PDAC 3D model to decipher immune infiltration. Thomas BESSEDE. IRCM, Montpellier, France.

B046 Sensitizing the PDAC tumor microenvironment to immune checkpoint therapies: characterization of a PDAC 3D model to decipher immune infiltration. Thomas BESSEDE. IRCM, Montpellier, France.

B047 Antigenic properties determine the outcome of B cell driven anti-tumor immunity. Colleen Sturdevant. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

B048 Lipopolysaccharide (LPS) mediated Toll like receptor-4 (TLR4) agonism immunomodulates pancreatic cancer niche via CD4+ T cells-Myeloid cells axis. Utpreksha Vaish. University of Alabama at Birmingham, Birmingham, AL, United States.



B049 Oncolytic virotherapy as an effective tool to synergistically enhance therapeutic efficacy of standard systemic treatments for pancreatic cancer. Conner Hartupee. Louisiana State University Health Sciences Center - New Orleans, New Orleans, LA, United States.

B050 Convergent signaling via C/EBP β regulates MDSC-intrinsic NLRP3 inflammasomes to drive inflammatory CAF polarization. Karthik Rajkumar. University of Miami, Miami, FL, United States.

B051 Influence of MUC16 on the immune tumor microenvironment of PDAC. Christabelle Rajesh. University of Nebraska Medical Center, Omaha, NE, United States.

B052 Single-cell and spatial analysis of the immune landscape unveils a subset of potentially tumor-reactive T cells in patients with localized PDAC. Elishama Kanu. Duke University Medical Center, Durham, NC, United States.

B053 SUMOylation and TIGIT inhibition: a novel immunotherapy combination for pancreatic cancer. Jorge de la Torre Medina. UC San Diego Health, San Diego, CA, United States.

B054 Protease activity as a biomarker and potential target among pancreatic cancer patients. Utsav Joshi. UCSD, San Diego, CA, United States.

B055 Harnessing cytomegalovirus immunity against pancreatic tumors for immunotherapy. Tatiana Hurtado de Mendoza. University of California San Diego, La Jolla, CA, United States.


B056 Discovery and therapeutic potential of novel cryptic peptides in pancreatic cancer. Gurcan Gunaydin. Dana-Farber Cancer Institute, Boston, MA, United States.

B057 The circadian master regulator BMAL1 blocks immune cell recognition of pancreatic ductal adenocarcinomas via tumor-derived interleukin-1 receptor antagonist. Orjola Prela. University of Rochester, Rochester, NY, United States.

B058 Rewiring CD8⁺ T cell responses to PD-1 immune checkpoint blockade in PDAC via the inhibitory receptor PSGL-1. Jennifer Hope. Drexel University, Philadelphia, PA, United States.

B059 Modulating the immunosuppressive pancreas tumor microenvironment through intratumoral delivery of cytokine-encoding mRNAs. Chaitanya Naimesh Parikh. University of Massachusetts Chan Medical School, Worcester, MA, United States.

B060 Unveiling resistance mechanisms to CAR T-cell therapy in pancreatic cancer through in vivo CRISPR/Cas9 knockout screening. Julia Fröse. MIT, Cambridge, MA, United States.



B061 Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy. Mark O'Hara. University of Pennsylvania, Philadelphia, PA, United States.

B062 Low dose dual epigenetic therapy utilizing hypomethylating agents and HDAC inhibitors prolong survival in an orthotopic PDAC model and alter the tumor microenvironment. Stephen Muzyka. NYU Langone, New York, NY, United States.

B063 Elucidating treatment induced tumor antigen presentation in pancreatic cancer Emma Adhikari¹, Andrew Weeden¹, Emily Brennan¹, Christopher Polera¹, Victoria Izumi², Bin Fang², John Koomen², Paul Stewart³, Alex Jaeger¹. Emma Adhikari. Moffitt Cancer Center, Tampa, FL, United States.

B064 Antigen-presenting type-I conventional dendritic cells facilitate curative checkpoint blockade immunotherapy in pancreatic cancer. Krishnan Mahadevan. MD Anderson Cancer Center, Houston, TX, United States.

B065 Eosinophils alter metastatic spread in pancreatic cancer. Megan Hoffman. Dana Farber Cancer Institute, Boston, MA, United States.


B066 An AI approach to unraveling treatment response in pancreatic cancer: Insights from the COMPASS trial leveraging large language models (LLMs). Joseph Geraci. Queen's University, Kingston, ON, Canada.

B067 Temporally resolved proteomics identifies nidogen-2 as a co-target in pancreatic cancer that modulates fibrosis and therapy response. Paul Timpson. The Garvan Institute of Medical Research, Sydney, Australia.

B068 Human pancreatic cancer single cell atlas reveals association of CXCL10 positive fibroblasts and basal subtype tumor cells. Ian Loveless. Henry Ford Health System, Detroit, MI, United States.

B070 TGFB2 mRNA levels prognostically interact with Interferon-alpha receptor activation of IRF9 and IFI27, and makers for tumor-associated macrophages impacting overall survival in PDAC. Wen-Han Chang. Oncotelic Therapeutics Inc, Agoura Hills, CA, United States.

B071 Antigen-presenting cancer-associated fibroblasts are required for ICI-sensitivity in pancreatic ductal adenocarcinoma. Saumya Maru. Johns Hopkins University, Baltimore, MD, United States.



B072 Pharmacological depletion of fibrinogen suppresses the growth of primary tumors and liver metastasis of pancreatic cancer. Melissa Fishel. Indiana University School of Medicine, Indianapolis, IN, United States.

B073 Organ-specific diversity of tumor immune microenvironment in metastatic pancreatic cancer. Jimin Min. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B074 Aberrant pericytes in PDAC: effects on endothelial-pericyte adhesion, vascular integrity, and tumor microenvironment. Vikneshwari Natarajan. North Dakota State University, Fargo, ND, United States.

B075 Functional characterization of TGF- β -dependent cancer-associated fibroblasts in pancreatic cancer using novel in vitro and in vivo models. Priscilla Cheng. Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.

B076 Morphological diversity predicts functional traits in pancreatic cancer. Dennis Gong. MIT, Cambridge, MA, United States.

B077 Altered mRNA splicing mimics chromosome loss and drives pancreatic cancer. Natasha Pinto Medici. Yale University, New Haven, CT, United States.

B078 A comprehensive spatial atlas of neoadjuvant chemoradiation therapy in resected pancreatic cancer identifies cellular & microenvironmental determinants of persister populations. Vincent Bernard. MD Anderson Cancer Center, Houston, TX, United States.

B079 Disassembly of embryonic keratin filaments promotes pancreatic cancer metastases. Deanne Yugawa. Yale University, New Haven, CT, United States.

B080 A porcine model of pancreatic ductal adenocarcinoma for human scale translational cancer research. Laura Beltrán Sangüesa. Technical University of Munich, Freising, Germany.

B081 In situ multi-modal characterization of pancreatic ductal adenocarcinoma reveals tumor cell identity as a defining factor of the surrounding microenvironment. Eugene Drokhyansky. Bristol Myers Squibb, Cambridge, MA, United States.

B082 Oncogenic KRAS-mediated epigenetic reprogramming is altered by loss of Activating Transcription Factor 3. Fatemeh Mousavi. Western University, London, ON, Canada.

B083 The splicing factor SMNDC1 facilitates alternative RNA splicing, contributing to therapy resistance in pancreatic cancer. Md Afjalus Siraj. Yale University, New Haven, CT, United States.



B084 Comparative functional analysis of TP53 alleles in pancreatic ductal adenocarcinoma in vivo. Sherry Agabiti. Yale University, West Haven, CT, United States.

B085 The HIF-2 transcription factor mediates resistance to ferroptosis in pancreatic adenocarcinoma. Maimon Hubbi. Johns Hopkins University School of Medicine, Baltimore, MD, United States.

B086 Patient-derived pancreatic tumor organoids as a tool to evaluate cancer stem cell populations and their role in therapeutic resistance. William Ryan. University of Maryland, School of Medicine, BALTIMORE, MD, United States.

B087 The circadian rhythm gene Dec2 regulates multiple components of the antigen presentation pathway to promote pancreatic cancer dormancy by immune evasion. Chris Harris. University of Rochester Medical Center, Rochester, NY, United States.

B088 Epigenetic reprogramming in ATM-deficient pancreatic cancer: targeting EZH2-mediated oncogenic traits. Elodie Roger. Institute for Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany.

B089 Identification of novel drivers of gemcitabine resistance in pancreatic cancer. Amina Bilalbegovic. Cornell University, Ithaca, NY, United States.

B090 Evaluating the molecular determinants of PDAC racial health disparities. Anthony Johansen-Sallee. University of Nebraska Medical Center, Omaha, NE, United States.

B091 Spatial Transcriptomics Unveils Intraductal Papillary Mucinous Neoplasm Heterogeneity: From Novel Clusters to Immune Dynamics. Amaya Pankaj. MGH Cancer Center, Charlestown, MA, United States.

B092 PP2A activation alters macropinosome processing in pancreatic cancer cells leading to metabolic stress and cancer cell death. Brittany Allen-Petersen. Purdue University, West Lafayette, IN, United States.

B093 The evaluation of the gene expression profile of pancreatic ductal adenocarcinomas (PDACs) in 3D cell culture vs in vivo and development of new 3D PDACs' models for an evaluation of anti-cancer drug testing. Marcin Krzykawski. Real Research, Krakow, Poland.



Poster Session C (To be presented Tuesday, September 17, 6:45-9p.m.)

C001 Transforming Growth Factor- β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy in Mice. Li Qiang. Dana-Farber Cancer Institute, Boston, MA, United States.

C002 A pilot study to assess the safety, tolerability, and tumor responses with lenvatinib plus pembrolizumab in patients with advanced pancreatic ductal adenocarcinoma in second-line or later of treatment. Brandon Smaglo. MD Anderson Cancer Center, Houston, TX, United States.

C003 A phase II study of peri-operative NovoTTF-200T(P) in combination with gemcitabine and nab-paclitaxel for resectable pancreatic adenocarcinoma big ten cancer research consortium BTCRC-GI21-500. Ashish Manne. The Ohio State University, Columbus, OH, United States.

C004 A window-of-opportunity trial using neoadjuvant hepatic artery chemotherapy for patients with localized pancreas cancer: Interim analysis of safety and feasibility. Ethan Agritelley. Duke University School of Medicine, Durham, NC, United States.

C005 Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer. Hadas Reuveni. Purple Biotech, Rehovot, Israel.

C006 LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair (HRR) Genes. Sriram Anbil. University of Pennsylvania, Philadelphia, PA, United States.

C007 Quemliclustat (CD73 Inhibitor) reduces adenosine-regulated NR4A gene expression and increases mPDAC inflammation in patients from the ARC-8 trial. Ning Wang. Arcus Biosciences, Hayward, CA, United States.

C008 Patient-derived organoids and precision medicine: Insights from the PASS-01 clinical trial in PDAC. Amber Habowski. CSHL, Cold Spring Harbor, NY, United States.

C009 Genomic and transcriptomic characterization of pancreatic cancer patients on the PASS-01 trial. Grainne O'Kane. Princess Margaret Cancer Centre, Toronto, ON, Canada.

C010 Single-cell profiling unleashes KRAS-driven redrafting of the tumor microenvironment before cancer onset. Chantal Allgoewer. Institute of Molecular Oncology and Stem Cell Biology, University Hospital Ulm, Ulm, Germany.

C011 Targeting STAT3 overcomes PDAC resistance to EGFR/RAF1 inhibition leading to complete and durable tumor regression. Vasiliki Liaki. Spanish National Cancer Research Center (CNIO), Madrid, Spain.



C012 Overcoming Cell Subtype-Specific Adaptive Resistance to KRAS G12D Inhibition in KRAS G12D-Mutant Pancreatic Cancer. Qingxiang (Nick) Lin. Massachusetts General Cancer Center, Boston, MA, United States.

C013 Evaluating direct KRASQ61H inhibition in pancreatic cancer models. Andrew Waters. University of Cincinnati, Cincinnati, OH, United States.

C015 Selective and pairwise epistatic effects of somatic mutations in KRAS wild-type pancreatic cancer. Rishi Shah. Department of Applied Mathematics, Yale College, New Haven, CT, United States.

C016 Pancreatitis-induced resistance to KRAS targeted therapy: The role of cellular plasticity and underlying mechanisms. Pingping Hou. Rutgers University New Jersey Medical School, Newark, NJ, United States.

C017 Targeting KRAS selectively induce metabolic reprogramming in pancreatic cancer. Zeribe Nwosu. Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY, United States.

C018 Targeting KRAS inhibitor resistance by ferroptosis induction in PDAC. Aparna Padhye. Dana-Farber Cancer Institute, Boston, MA, United States.

C019 A novel SDC1-targeted therapeutic antibody inhibits macropinocytosis and induces anti-tumor immunity in pancreatic cancer. Zecheng Yang. MD Anderson Cancer Center, Houston, TX, United States.

C020 Identification of KRAS-specific TCRs from human peripheral blood. Jiao Shen. Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

C021 Identifying synergistic combinations with KRAS inhibition in PDAC. Fredrik Thege. MD Anderson Cancer Center, Houston, TX, United States.

C022 Elucidation and exploitation of RAS-inhibitor dependent macropinocytic regulation in pancreatic ductal adenocarcinoma. Ryan Robb. University of North Carolina Chapel Hill, Chapel Hill, NC, United States.

C023 PDAC tumors from patients treated with combination MEK and autophagy inhibition reveal a treatment sensitive epithelial subtype that is enriched in murine models. Brian Labadie. Columbia University Irving Medical Center, New York, NY, United States.

C024 Quantitative mass spectrometry-based multi-omic profiling to overcome drug resistance in pancreatic cancer post KRAS G12D inhibition. Qijia Yu. Dana-Farber Cancer Institute, Boston, MA, United States.



C025 A novel pan-RAS/ β -catenin inhibitor, ADT-030, produces tumor regression in PDX models of pancreatic cancer. Gary Piazza. Auburn University Harrison College of Pharmacy, Auburn, AL, United States.

C026 Concurrent inhibition of the RAS ERK-MAPK pathway and PIKfyve as a therapeutic strategy for pancreatic cancer. Jonathan DeLiberty. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

C027 Efficacy advantages of a novel pan-RAS inhibitor, ADT-1004, over mutant-specific KRAS inhibitors for suppressing pancreatic tumor growth in murine models. Jeremy Foote. University of Alabama at Birmingham, Birmingham, AL, United States.

C028 Challenging PDAC adaptability: Uncovering therapeutic vulnerabilities in APE1 DNA repair mechanisms. Eyram Kpenu. Indiana University School of Medicine, Indianapolis, IN, United States.

C029 Window-of-opportunity trial of metastatic pancreatic cancer reveals potential mechanisms of response to targeting RAS/MEK signaling. Motoyuki Tsuda. OHSU, portland, OR, United States.

C030 Evolutionary and epistatic analyses reveal genic interactions with KRAS during malignant progression of pancreatic ductal adenocarcinoma. Nic Fisk. University of Rhode Island, North Kingston, RI, United States.


C031 Keratin 17 promotes pancreatic cancer chemoresistance through mitochondrial translocation and stabilization of dihydroorotate dehydrogenase (DHODH). Yinghuan Lyu. Stony Brook University, STONY BROOK, NY, United States.

C032 De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer. huan zhang. Dana-Farber Cancer Institute, Boston, MA, United States.

C033 Targeting PIKfyve-driven lipid metabolism in pancreatic cancer. Caleb Cheng. University of Michigan, Ann Arbor, MI, United States.

C034 MUC1 positive extracellular vesicles play an important role on gemcitabine resistance in PDAC. Ying Huang. University of Nebraska Medical Center, Omaha, NE, United States.

C035 MAGEA6 Oncogene Upregulates MAPK and AMPK Signaling Pathways in Pancreatic Cancer Cells to Promote Survival under Nutrient Stress: Resistance to Glycolysis Inhibition and Increased Susceptibility to Glutamine Depletion. Sima Tozandehjani. Texas Tech University, Amarillo, TX, United States.



C036 Vertical inhibition of the autophagy pathway enhances sensitization to RAS MAPK pathway inhibition in pancreatic ductal adenocarcinoma. Mallory Roach. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

C037 Characterization of cysteine dependency implicates glutathione metabolism as a critical adaptation axis in pancreatic cancer. Chiamaka Ezeh. Cornell University, Ithaca, NY, United States.

C038 Cancer-associated fibroblasts maintain critical pancreatic cancer cell lipid homeostasis in the tumor microenvironment. Xu Han. University of Pennsylvania, Philadelphia, PA, United States.

C039 Investigating ER stress responses in pancreatic ductal adenocarcinoma under lipid imbalance. Yanqing (Christine) Jiang. University of Pennsylvania, Philadelphia, PA, United States.

C040 RNF43 Loss Induces an IRE1-dependent Metabolic Reprogramming in Pancreatic Cystic Neoplasms. Akiko Sagara. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

C041 Emerging role of P2X receptors as Golgi pH regulators in pancreatic cancer. Cheska Marie Galapate. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.

C042 Identification of a non-canonical pathway used by CAF to deliver gamma-aminobutyric acid in pancreatic cancer. Ariana Musa de Aquino. Henry Ford Hospital, Deroit, MI, United States.


C043 Hyperinsulinemia promotes pancreatic cancer progression by altering tumor metabolism. Jeffrey Lin. The University of British Columbia, Vancouver, BC, Canada.

C044 PI5P4K α regulates cell fitness through iron homeostasis in pancreatic cancer. Gurpreet Kaur Arora. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.

C045 Targeting metabolic heterogeneity in pancreatic ductal adenocarcinoma. Taryn Morningstar. University of California, Irvine, Irvine, CA, United States.

C046 Targeting wild-type IDH1 sensitizes homologous recombination proficient pancreatic cancer to PARP inhibition. Mehrdad Zarei. Case Western Reserve University, Cleveland, OH, United States.

C047 Autophagy-mediated proline-supply is important for cell survival in pancreatic cancers. Ji hyeon Kim. Research Institute National Cancer Center, KOREA, National Cancer Center Graduate School of Cancer Science and Policy., Goyang, Korea, Republic of.



C048 Hecpudin-mediated iron sequestration limits CD8+ tumor infiltrating lymphocytes in pancreas adenocarcinoma. Joshua Schoenfeld. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

C049 Computational Methods for Central and Lipid Metabolism Networks Analysis to Reveals Flux Change in PDAC. Sha Cao. OHSU, Portland, OR, United States.

C050 Vitamin B6 restriction impairs pancreatic cancer progression. Chunbo He. University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.

C051 Cell polarity proteins as novel regulators of macropinocytosis. Guillem Lambies Barjau. Sanford Burnham Prebys Medical Discovery Institute, LA JOLLA, CA, United States.

C052 Repurposing Statins to Target Gemcitabine Resistance in Pancreatic Cancer. Sabrina Calderon. University of California, Irvine, Alhambra, CA, United States.

C053 Pancreatic cancer patient-derived organoids, preclinical tools for therapeutic profiling, patient response prediction, and tumor evolution. Johann Gout. Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany.

C054 Clinicogenomic determinants of response to FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line systemic therapy for pancreatic cancer. Kunling Tong. Duke University, Durham, NC, United States.


C055 Unraveling pancreatic cancer susceptibility at 5p15.33: Functional characterization of a novel VNTR element. Aidan O'Brien. National Cancer Institute, Rockville, MD, United States.

C056 Characterization of chromatin accessibility patterns in the human pancreas and early pancreatic neoplastic lesions using snATAC-seq. Jamie Mills. University of Michigan, Ann Arbor, MI, United States.

C057 Tumor molecular features associated with estimated genetic ancestry of patients with pancreatic ductal adenocarcinoma. Ling Huang. Henry Ford Health, Detroit, MI, United States.

C058 A novel approach to understanding pancreas cancer risk through enhancer-promoter interactions. Efsun Arda. National Institutes of Health, Bethesda, MD, United States.

C059 Regulatory Elements of Pancreas Development License the Initiation of Pancreatic Ductal Adenocarcinoma. Luis Arnes. University of Copenhagen, Copenhagen, Denmark.



C060 Temporal stability and chemotherapy responsiveness of classical and basal transcriptional subtypes of pancreatic cancer. Harshabad Singh. Dana-Farber Cancer Institute, Boston, MA, United States.

C061 Loss of CaMK2B accelerates tumor formation and enhances metastatic competency in genetically engineered mouse models of PDAC. Jessica Peura. University of Massachusetts Chan Medical School, Worcester, MA, United States.

C063 Inhibition of PRMT5 reduces aggressiveness in basal-like pancreatic ductal adenocarcinoma. Christina Wang. University of Rochester, Rochester, NY, United States.

C064 Mapping cellular plasticity through the lens of FRA1 during KrasG12D mediated pancreatic acinar to ductal metaplasia. Noriyuki Nishiwaki. Division of Digestive and Liver Diseases, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, United States.

C065 PlastiNet: Understanding the Epithelial - Mesenchymal Transition Through Graphical Attention in Spatial Transcriptomics. Izabella Zamora. Broad Institute, Cambridge, MA, United States.

C066 Identifying Transcriptional Drivers of Plasticity in Pancreatic Cancer. Yuzhou Tong. MIT, Cambridge, MA, United States.

C067 Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer. Daniel Salas-Escabillas. Henry Ford Health, Detroit, MI, United States.


C068 Phenotypic plasticity and functional divergence of neutrophilic MDSCs in pancreatic cancer. Anna Bianchi. University of Miami, Miami, FL, United States.

C069 A conserved reepithelialization program driven by FOSL1 underlies malignancy in pancreatic ductal adenocarcinoma. Charles David. Tsinghua University School of Medicine, Beijing, China (Mainland).

C070 Keratin 17 and GATA6 correlate with diffusely infiltrative versus gland-forming components of PDAC: Uncovering the transitional state in pancreatic ductal adenocarcinoma. Lyanne Delgado-Coka. Stony Brook University, East Hampton, NY, United States.

C071 Transcription factor switching drives progression of the classical subtype of pancreatic cancer. Shalini Rao. University of Cambridge, Cambridge, United Kingdom.

C072 Bmi1 expression is upregulated in response to injury/stress in the pancreas. Nur Muhammad Renollet. University of Michigan, Ann Arbor, MI, United States.



C073 FOLFIRINOX with Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor Elraglusib and Transforming Growth Factor- β (TGF β) Inhibitor Losartan in Untreated Metastatic Pancreatic Ductal Adenocarcinoma(PDAC): Interim analysis of safety cohort.

Priyadarshini Pathak. Massachusetts General Hospital, Boston, MA, United States.

C074 Influence of Cell Death and Stress on the Tumor Microenvironment and EMT in Pancreatic Ductal Adenocarcinoma Through Single Cell and Spatial Transcriptomics.

Rahul Bansal. Broad Institute, Boston, MA, United States.

C075 Ror2, a Novel Key Regulator Driving Cell Fate Decisions throughout Pancreatic Carcinogenesis.

Simone Benitz. Henry Ford Health, Detroit, United States.

C076 Transcriptomic analyses of normal human pancreatic acinar cells reveal the presence of cancer subtypes that correlate with acinar ductal metaplasia.

Thomas Schmittgen. University of Florida, Gainesville, FL, United States.

C077 Functional Dissection of the Highly Plastic Basal Cell State in Pancreatic Cancer.

Anupriya Singhal. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

C078 Chromatin accessibility profiling of human pancreatic tumors reveals epigenetic features of malignant and stromal cell subtypes.

Kevin MacPherson-Hawthorne. Oregon Health & Science University, Portland, OR, United States.

C079 Exploring acinar to ductal metaplasia in pancreatitis and precancerous contexts using FixNCut.

Katherine Aney. Brigham and Women's Hospital, Boston, MA, United States.